IFNA17 and neoplasm: In a study enrolling patients with progressive, metastatic NETs, including GEP-NETs, conducted by Faiss et al., the therapy with lanreotide 1 mg three times daily or interferon-α (INF-α) 5 × 106 U three times weekly or lanreotide 1 mg three times daily + INF-α 5 × 106 U three times weekly had not given significant Cg A reduction among treatment groups and the biochemical response did not correlate with inhibition of tumor growth [75].